Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2021

View Archived Issues

Study unveils a mechanistic link between LRRK2, AP2 and endocytosis in the pathogenesis of PD

Inhibition of PIP4K can be used to control regulatory T-cell activity

Novel oxidative-phosphorylation inhibitors with promising antitumor activity in vivo

Discovery of CPL-302415 as promising preclinical candidate for SLE

Loss of fbn2b tied to cardiovascular manifestations overlapping with Marfan syndrome

Eternity Bioscience patents new ADAMTS inhibitors

Fileclo Sp zoo discloses new compounds for cancer

Arbutus Biopharma identifies PD-L1 antagonists

Japanese researchers synthesize new PROTACs for cancer

Rockefeller University presents new LATS1 inhibitors

Biallelic THUMPD1 variants linked to syndromic intellectual developmental disorder

Merck & Co. structure-based design efforts lead to new nucleoside PRMT5 inhibitors

ErSO induces regression of human breast tumors in vivo

Researchers identify genetic associations with behaviors related to self-regulation and addiction

Jacobio invests in Hebecell to advance iPSC-NK cell therapy

AcureX awarded funding to support development of drug candidates for Parkinson's disease

Mindset Pharma reports preclinical data on next-generation novel 5-MeO-DMT psychedelic analogues

COL13A1 and KCNMA1 are downregulated in patients with Pompe disease

Janssen optimizes new series of PDE2A inhibitors

SPOP gene behind prostate cancer risk

All is loss for P53 mutations, study argues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...